Skip to main content
Clinical Trials/NCT00869011
NCT00869011
Unknown
Phase 3

Effects of Physical Activity on the Endothelial and Cardiac Function of Patients With Renal Cell Carcinoma Receiving a Thyrosine Kinase Inhibitor (Sunitinib)

Charite University, Berlin, Germany1 site in 1 country70 target enrollmentDecember 2009

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Renal Cell Carcinoma
Sponsor
Charite University, Berlin, Germany
Enrollment
70
Locations
1
Primary Endpoint
Fatigue
Last Updated
16 years ago

Overview

Brief Summary

In this randomized, controlled trial the investigators evaluate the effects of an exercise program lasting for 12 weeks on the physical performance, the cardiovascular function (24h blood pressure, rest blood pressure and hear function) and the fatigue and mood of patients with renal cell carcinoma undergoing a therapy with Sunitinib.

Registry
clinicaltrials.gov
Start Date
December 2009
End Date
June 2011
Last Updated
16 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 18 to 75 years
  • Understanding of written German
  • Treatment with Sunitinib
  • Ability to walk

Exclusion Criteria

  • Cardiovascular, pulmonary or osteoarticular disease which can be aggravated by exercise
  • BMI \< 18 or \> 30

Outcomes

Primary Outcomes

Fatigue

Time Frame: 12 weeks

Secondary Outcomes

  • VO2max(12 weeks)
  • Depression score(12 weeks)
  • Systolic and diastolic blood pressure (24 h)(12 weeks)

Study Sites (1)

Loading locations...

Similar Trials